[Acute adverse effects following administration of liposomal amphotericin B].
Portillo-Cano
María del Mar
Mdel M
Lobo-Acosta
María Angeles
MA
Ríos-Villegas
María José
MJ
Alanís-López
Joaquín
J
D000368:Aged; D000666:Amphotericin B / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000175:diagnosis; D001170:Arthritis, Infectious / Q000188:drug therapy; D041221:Candida glabrata; D002177:Candidiasis / Q000188:drug therapy; D002637:Chest Pain / Q000139:chemically induced* / Q000175:diagnosis; D003937:Diagnosis, Differential; D004417:Dyspnea / Q000139:chemically induced* / Q000175:diagnosis; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous / Q000009:adverse effects; D007720:Knee Prosthesis; D008081:Liposomes / Q000008:administration & dosage / Q000009:adverse effects; D016459:Prosthesis-Related Infections / Q000188:drug therapy; D012008:Recurrence; D013577:Syndrome
D000935:Antifungal Agents; D008081:Liposomes; C068538:liposomal amphotericin B; D000666:Amphotericin B